Pfizer Inc. (PFE) Debt to Equity Ratio: 0.78
Is Pfizer Inc.’s debt to equity ratio high or low?
Pfizer Inc.'s debt to equity ratio of 0.78 is 23% above its 5-year average of 0.63, near the high end of its 5-year range (0.36–0.80).
As of Thursday, June 11, 2026. 1.30% above its 12-month average of 0.77.
PFE Debt to Equity Ratio Chart
PFE Average Debt to Equity Ratio Chart
PFE Current vs Average Debt to Equity Ratio Chart
PFE Debt to Equity Ratio Metrics
DEBT TO EQUITY RATIO
0.78
DEBT TO EQUITY RATIO AVG TTM
0.77
DEBT TO EQUITY RATIO AVG 3Y
0.68
DEBT TO EQUITY RATIO AVG 5Y
0.63
DEBT TO EQUITY RATIO AVG 10Y
0.65
DEBT TO EQUITY RATIO AVG 15Y
0.60
DEBT TO EQUITY RATIO AVG 20Y
0.52
CURRENT VS TTM AVG
+1.30%
CURRENT VS 3Y AVG
+15.56%
CURRENT VS 5Y AVG
+23.48%
CURRENT VS 10Y AVG
+20.00%
CURRENT VS 15Y AVG
+30.41%
CURRENT VS 20Y AVG
+49.04%
PFE Competitors' Debt to Equity Ratio
| NAME | MARKET CAP | DEBT TO EQUITY RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Pfizer Inc. (PFE) | $149.61B | 0.78 | 0.77 | 0.68 | 0.63 |
| Intuitive Surgical, Inc. (ISRG) | $144.79B | 0.02 | 0.01 | 0.01 | 0.01 |
| Abbott Laboratories (ABT) | $155.75B | 0.29 | 0.30 | 0.38 | 0.44 |
| Gilead Sciences, Inc. (GILD) | $156.35B | 1.09 | 1.23 | 1.19 | 1.29 |
| CVS Health Corporation (CVS) | $126.70B | 1.24 | 1.17 | 1.09 | 1.10 |
| Danaher Corporation (DHR) | $126.39B | 0.35 | 0.35 | 0.37 | 0.43 |
| Thermo Fisher Scientific Inc. (TMO) | $176.21B | 0.76 | 0.71 | 0.76 | 0.76 |
| Bristol-Myers Squibb Company (BMY) | $116.13B | 2.55 | 2.84 | 2.10 | 1.84 |
| Amgen Inc. (AMGN) | $188.37B | 6.31 | 8.27 | 9.39 | 7.67 |
| Vertex Pharmaceuticals Incorporated (VRTX) | $110.59B | 0.21 | 0.16 | 0.11 | 0.11 |
Financial Health
Debt/Equity
0.78
Current Ratio
1.16
Pfizer Inc. Debt to Equity Ratio Formula & Definition
Debt to Equity measures financial leverage by comparing total debt to shareholders' equity.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Pfizer Inc. Debt to Equity Ratio FAQ
- What is the debt to equity ratio for Pfizer Inc. (PFE)?
- The debt to equity ratio for PFE stock is 0.78.
- Is Pfizer Inc.'s debt to equity ratio high or low?
- Pfizer Inc.'s debt to equity ratio of 0.78 is 23% above its 5-year average of 0.63, near the high end of its 5-year range (0.36–0.80).
- What is the TTM average debt to equity ratio for Pfizer Inc. (PFE)?
- The TTM average debt to equity ratio for PFE stock is 0.77.
- What is the 3Y average debt to equity ratio for Pfizer Inc. (PFE)?
- The 3Y average debt to equity ratio for PFE stock is 0.68.
- What is the 5Y average debt to equity ratio for Pfizer Inc. (PFE)?
- The 5Y average debt to equity ratio for PFE stock is 0.63.
- What is the 10Y average debt to equity ratio for Pfizer Inc. (PFE)?
- The 10Y average debt to equity ratio for PFE stock is 0.65.
- What is the 15Y average debt to equity ratio for Pfizer Inc. (PFE)?
- The 15Y average debt to equity ratio for PFE stock is 0.60.
- What is the 20Y average debt to equity ratio for Pfizer Inc. (PFE)?
- The 20Y average debt to equity ratio for PFE stock is 0.52.
Pfizer Inc. Debt to Equity Ratio History
| DATE | DEBT TO EQUITY RATIO |
|---|---|
| 2025-12-31 | 0.78 |
| 2024-12-31 | 0.76 |
| 2023-12-31 | 0.80 |
| 2022-12-31 | 0.36 |
| 2021-12-31 | 0.48 |
| 2020-12-31 | 0.61 |
| 2019-12-31 | 0.81 |
| 2018-12-31 | 0.66 |
| 2017-12-31 | 0.60 |
| 2016-12-31 | 0.69 |
| 2015-12-31 | 0.60 |
| 2014-12-31 | 0.51 |
| 2013-12-31 | 0.48 |
| 2012-12-31 | 0.46 |
| 2011-12-31 | 0.47 |
| 2010-12-31 | 0.50 |
| 2009-12-31 | 0.54 |
| 2008-12-31 | 0.30 |
| 2007-12-31 | 0.20 |
| 2006-12-31 | 0.11 |
| 2005-12-31 | 0.27 |
| 2004-12-31 | 0.27 |
| 2003-12-31 | 0.22 |
| 2002-12-31 | 0.59 |
| 2001-12-31 | 0.48 |
| 2000-12-31 | 0.34 |
| 1999-12-31 | 0.80 |
| 1998-12-31 | 0.37 |
| 1997-12-31 | 0.38 |
| 1996-12-31 | 0.42 |
Related Metrics
About Pfizer Inc.
Pfizer Inc. is a global biopharmaceutical leader engaged in the research, development, production, marketing, and distribution of a wide array of medicinal and vaccine products worldwide. Its comprehensive portfolio addresses diverse therapeutic areas, including cardiovascular health and women's health, featuring key brands such as the Premarin family and Eliquis. The company also offers advanced biologics, small molecule drugs, immunotherapies, and biosimilars for various conditions, exemplified by Ibrance, Xtandi, and Retacrit. Furthermore, Pfizer provides sterile injectables, anti-infective agents, and a significant oral treatment for COVID-19, including Paxlovid. A substantial portion of its offerings comprises vaccines for infectious diseases such as pneumococcal and meningococcal disease, tick-borne encephalitis, and COVID-19, with notable products like Comirnaty and the Prevnar family. The firm also develops biosimilars for chronic autoimmune and inflammatory disorders, including Inflectra and Xeljanz, alongside specialized therapies for rare conditions like amyloidosis, hemophilia, and endocrine disorders, under brands such as Vyndaqel and BeneFIX. Beyond its proprietary products, Pfizer operates a contract manufacturing division. Its extensive customer base includes wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual medical practices, and public health organizations. The company actively fosters strategic collaborations with numerous partners, such as Bristol-Myers Squibb Company, BioNTech SE, and Merck KGaA. Established in 1849, Pfizer Inc. is headquartered in New York, New York.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Albert Bourla